Puma Biotechnology (PBYI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Puma Biotechnology

NasdaqGS•Healthcare•Biotechnology

$9.24-0.01(<0.01%)Market open

Market Cap

$470.69M

P/E

17.6x

P/S

2.0x

P/B

3.4x

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

How this company scores

AverageMetricSide Score: 51/100

Strongest: Profitability (17/25); weakest: Growth (3/25).

Profitability17/25

Growth3/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality16/25

Strengths

High ROEInterest easily coveredConsistent free cash flowNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.6x5y range 3.5x – 97000.3x

Currently above its 15-quarter median.

P/S · 2.0x5y range 0.5x – 2.0x

Currently above its 20-quarter median.

P/B · 3.4x5y range 1.5x – 16.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 36.8% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $470.69M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $231.24M
Q. Revenue: $56.50M
TTM EBITDA: $43.58M
TTM Op. Income: $30.44M
Q. Op. Income: $7.58M
TTM Net Income: $26.72M
Q. Net Income: $8.19M
EPS: $0.16
Shares Out.: $50.94M

$231.24M in TTM revenue declined 2.9% YoY, reaching $56.50M last quarter. TTM EBITDA of $43.58M and TTM operating income of $30.44M show growth is flowing through to the bottom line. TTM net income of $26.72M means revenue is converting into profit. Over the past year, TTM revenue is down 3% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 17.9%
Op. Margin: 13.4%
Net Margin: 14.5%

Op. margin of 13.4% is up 0.8% YoY — cost efficiency is improving. Net margin at 14.5% Over the past year, operating margin is up 6% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 17.6x
P/S Ratio: 2.0x
P/B Ratio: 3.4x

At 17.6x P/E, the stock trades within typical market levels. P/S of 2.0x and P/B of 3.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $192.74M
Cash: $36.54M
Long-Term Debt: N/A
Book Value: $138.54M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.62M
TTM Free Cash Flow: $41.16M
FCF Margin: 17.8%
FCF / Net Income: 1.5

TTM FCF of $41.16M on $1.62M in operating cash flow. The FCF / Net Income ratio of 1.5x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 7% — a weakening trend.